梅花生物
(600873)
| 流通市值：298.97亿 | | | 总市值：298.97亿 |
| 流通股本：28.53亿 | | | 总股本：28.53亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,268,563,075.46 | 25,069,288,294.62 | 18,680,785,476.06 | 12,642,718,053.37 |
| 营业收入 | 6,268,563,075.46 | 25,069,288,294.62 | 18,680,785,476.06 | 12,642,718,053.37 |
| 二、营业总成本 | 5,214,885,039.05 | 21,862,599,657.62 | 16,648,960,494.8 | 11,156,817,653.82 |
| 营业成本 | 4,726,419,461.59 | 20,036,698,814.74 | 15,149,363,557.23 | 10,177,206,263.13 |
| 税金及附加 | 65,258,134.17 | 235,462,799.84 | 175,637,343.6 | 115,408,867.54 |
| 销售费用 | 86,222,231.72 | 386,866,509.47 | 290,839,474.29 | 204,453,466.84 |
| 管理费用 | 254,781,461.27 | 937,932,200.19 | 819,350,604.16 | 554,506,366.51 |
| 研发费用 | 103,233,375.21 | 382,903,265.05 | 285,461,019.6 | 180,479,234.74 |
| 财务费用 | -21,029,624.91 | -117,263,931.67 | -71,691,504.08 | -75,236,544.94 |
| 其中:利息费用 | 13,474,653.29 | 80,472,368.46 | 65,518,228.32 | 46,859,883.13 |
| 其中:利息收入 | 16,044,112.56 | 97,971,379.97 | 83,996,787.45 | 59,735,278.47 |
| 加:公允价值变动收益 | 9,346,362.95 | 14,826,169.53 | 8,763,064.93 | 1,959,926.94 |
| 加:投资收益 | 13,629,411.31 | 30,193,009.09 | 20,742,760.03 | 14,671,408.04 |
| 资产处置收益 | 138,287.86 | 29,968.32 | -2,427,954.12 | 1,598,224.17 |
| 资产减值损失(新) | -180,993.48 | -6,981,927.26 | -1,857,388.63 | -1,987,907.91 |
| 信用减值损失(新) | - | 3,888,525.41 | 6,173,620.92 | 6,162,617.22 |
| 其他收益 | 129,419,775.43 | 242,640,414.38 | 210,447,791.63 | 174,432,864.62 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,206,030,880.48 | 3,491,284,796.47 | 2,273,666,876.02 | 1,682,737,532.63 |
| 加:营业外收入 | 1,145,087.37 | 140,787,996.42 | 105,472,109.03 | 66,373,971.73 |
| 减:营业外支出 | 4,913,258.02 | 282,612,101.76 | 37,189,601.53 | 31,820,702.21 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,202,262,709.83 | 3,349,460,691.13 | 2,341,949,383.52 | 1,717,290,802.15 |
| 减:所得税费用 | 183,556,343.37 | 609,033,475.57 | 346,627,735.23 | 243,467,012.23 |
| 六、净利润 | 1,018,706,366.46 | 2,740,427,215.56 | 1,995,321,648.29 | 1,473,823,789.92 |
| 持续经营净利润 | 1,018,706,366.46 | 2,740,427,215.56 | 1,995,321,648.29 | 1,473,823,789.92 |
| 归属于母公司股东的净利润 | 1,018,706,366.46 | 2,740,427,215.56 | 1,995,321,648.29 | 1,473,823,789.92 |
| (一)基本每股收益 | 0.36 | 0.94 | 0.68 | 0.5 |
| (二)稀释每股收益 | 0.36 | 0.94 | 0.68 | 0.5 |
| 八、其他综合收益 | -78,900,353.95 | -60,692,608.96 | 39,914,573.3 | -30,039,576.1 |
| 归属于母公司股东的其他综合收益 | -78,900,353.95 | -60,692,608.96 | 39,914,573.3 | -30,039,576.1 |
| 九、综合收益总额 | 939,806,012.51 | 2,679,734,606.6 | 2,035,236,221.59 | 1,443,784,213.82 |
| 归属于母公司股东的综合收益总额 | 939,806,012.51 | 2,679,734,606.6 | 2,035,236,221.59 | 1,443,784,213.82 |
| 公告日期 | 2025-04-22 | 2025-03-18 | 2024-10-23 | 2024-07-30 |
| 审计意见(境内) | | 标准无保留意见 | | |